Scientists at the Victor Chang Cardiac Research Institute, working with colleagues at the Vanderbilt University Medical Center, have developed a world-first, individualized risk prediction tool for ...
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...
Genetic testing identifies germline mutations, while genomic testing analyzes somatic mutations in tumors, influencing treatment options. Broader testing criteria are expanding access to genetic ...
Add Yahoo as a preferred source to see more of our stories on Google. A new "proteomic" blood test can accurately screen a newborn's DNA for thousands of rare, inherited diseases by analyzing just a ...
Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...
Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy The ...
A microfluidic device barely larger than a U.S. quarter and developed by a Rutgers University-led team can detect rare genetic mutations from a single drop of blood. A team led by Rutgers ...
Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results